|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.71 USD | -0.88% |
|
-2.78% | +115.69% |
Y-mAbs Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 84.82 million compared to USD 65.27 million a year ago. Net loss was USD 21.43 million compared to USD 95.57 million a year ago.
Basic loss per share from continuing operations was USD 0.49 compared to USD 2.19 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +115.69% | 644M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
Y-MABS THERAPEUTICS, INC. 
